Two products can carry the same label and still not be the same substance, which matters a lot more when something is being injected or used systemically
Foundayo showed ~12.4% at 72 weeks (ATTAIN)no direct comparison trial exists
Work with your team on a transition plan that includes meal structure, coping skills, and extra support to manage changes in hunger and fullness.
Survodutide is a dual co-agonist combining properties of GLP-1 and glucagon receptor agonism in a single peptide molecule that has also been evaluated in a phase 2 study for weight loss
Although preventable, DFS is a significant cause of morbidity, mortality, hospitalization, and reduction in quality of life of patients with diabetes
Selenium, antioxidants, cardiovascular disease, and all-cause mortality: a systematic review and meta-analysis of randomized controlled trials